ArticleOral and maxillofacial surgery2024
Factors related to risk of recurrence and recurrence free survival in ameloblastoma of the Jaws: A single centre retrospective analysis.
Article in Oral and maxillofacial surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and validation of a nomogram for predicting recurrence risk in pediatric ameloblastoma treated with conservative surgery.BMC oral health · 2026Article
- Race is a Contributing Factor to Clinico-Pathological Characteristics of Ameloblastoma at a Multi-Network Academic Hospital System.Journal of racial and ethnic health disparities · 2026Article
- A multi-center cross-sectional investigation ofPeerJ · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAmeloblastoma is a benign tumor originating from odontogenic epithelium with a global incidence of about 0.5 cases per million persons per year. The overall recurrence rate of ameloblastomas range from 55% -90%. In this retrospective study we have analyzed the factors associated with recurrence and recurrence free survival in ameloblastoma of the jaws.
methodsRetrospective chart review of 10 years was done from records directory. All demographic data, data on diagnostic modalities, clinical presentations, radiology, management and histology were taken into consideration. Kaplan Meir estimator was used to evaluate recurrence rate and Cox regression analysis (univariate and multivariate) was used to evaluate the odds ratio to find out the possible factors influencing risk of recurrence and influence recurrence free survival. ROC curve (Receiver Operating Characteristic) was used to find out the optimal cut off point for size of the lesion in predicting recurrence. A p value of < 0.05 was considered statistically significant at 95% confidence interval.
resultsA total of 75 patients had recurrence with a median follow up of 65 months. The overall 5 year RFS was 19.5%. Conventional ameloblastomas, cortical/ soft tissue invasion, conservative treatment and tumor size ≥ 4 cm were independent predictors of recurrence.
conclusionAggressive treatment is preferred for conventional ameloblastomas ≥ 4 cm with cortical/ soft tissue invasion.
Indexed as
Identifiers
39739058What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.